Summary
OBJECTIVES: To assess the use of the Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI), a version of the ESSDAI without the biological domain, for assessing potential eligibility and outcomes for clinical trials in patients with primary Sjögren's syndrome (pSS), according to the new ACR-EULAR classification criteria, from the UK Primary Sjögren's Syndrome Registry (UKPSSR).
METHODS: A total of 665 patients from the UKPSSR cohort were analysed at their time of inclusion in the registry. ESSDAI and ClinESSDAI were calculated for each patient.
RESULTS: For different disease activity index cut-off values, more potentially eligible participants were found when ClinESSDAI was used than with ESSDAI. The distribution of patients according to defined disease activity levels did not differ statistically (chi 2 p = 0.57) between ESSDAI and ClinESSDAI for moderate disease activity (score ≥5 and <14; ESSDAI 36.4%; ClinESSDA 36.5%) or high disease
Introduction
Primary Sjögren's syndrome (pSS) is an autoimmune rheumatic disease characterised by inflammation of the exocrine glands, inducing a reduction in tear and salivary production. The clinical presentation varies, ranging from sicca symptoms associated with fatigue and arthralgia to systemic extraglandular manifestations [1] . There is no definitive treatment for pSS, but several clinical trials with biological therapies are ongoing or planned [2] [3] [4] [5] . In order to assess systemic disease activity in pSS, the EU-LAR Sjögren's Syndrome Disease Activity Index (ESS-DAI) has been developed. This index consists of 12 domains, 11 related to organ involvement and one biological domain reflecting B-cell activity [6] . The levels of activity of each domain (ranging from 0 to 3 points) are multiplied by their respective weights (ranging from 1 to 7 points) to obtain the total score. A user guide has been published to help clinicians who use this tool [7] . ESSDAI has been shown to be reliable and sensitive to change [8] [9] [10] . Cutoff values of ESSDAI defining moderate (>5 and <14) and severe (>14) systemic disease activity and the reduction in the score that represents the minimal clinically important improvement (MCII) have been proposed [11] .
There is an issue when using the biological domain of the ESSDAI in studies aimed at finding new biomarkers for pSS or in clinical trials investigating drugs targeting Bcell activity. This domain comprises hypergammaglobulinaemia, raised IgG or low complement levels and/or cryoglobulinaemia. There is a risk of false positive associations between a potential new biomarker and systemic disease activity assessment because biomarkers are often correlated to B-cell activity, as is the biological domain of ESS-DAI, producing a risk of multicollinearity of the data. In other words, there is a rationale for an index detecting clinical changes independently of the biological effects of studied drugs in clinical trials. Such an index would also be useful in monitoring clinical systemic disease activity, without the need for immunological tests, in routine clinical practice. Therefore, the Clinical EULAR Sjögren's Syndrome Disease Activity Index (ClinESSDAI) score has recently been developed. ClinESSDAI includes the same domains as the ESSDAI score apart from the biological domain. The weightings of the remaining domains have been recalculated. This score has been validated through the same process used for the ESSDAI with the same data set. The reliability and sensitivity to change of ClinESSDAI are similar to those of ESSDAI. The same cut-off values for levels of disease activity (≥5 moderate activity, ≥14 high activity) and MCII (3 points improvement) as for ESSDAI have been validated [12] . Levels of activity for each domain and their respective weights are summarised in table 1. The UK Primary Sjögren's Syndrome Registry (UKPSSR) is a cohort of patients in the UK who fulfil the AmericanEuropean Consensus Group (AECG) classification criteria for pSS, and are included in a research database and a tissue bank [13, 14] . A previous paper discussed the eligibility of the UKPSSR cohort for clinical trials according to different criteria, including the ESSDAI [15] . The American College of Rheumatology / European League Against Rheumatism classification criteria (ACR-EULAR) for pSS were published in 2016 and will proba- bly supersede the AECG criteria in defining inclusion criteria in future clinical trials [16] . The objective of this study was to assess the impact of using ClinESSDAI, in comparison with ESSDAI, in the UKPSSR on the assessment of potential eligibility and the ability to demonstrate change with treatment for future controlled clinical trials in participants with pSS according to the ACR-EULAR criteria.
Methods
Patients were recruited to the UKPSSR from August 2009. Data used for analysis were extracted from the database registry on 24 June 2013. All participants provided written informed consent to be included in the UKPSSR. Research ethical approval for the UKPSSR was obtained from National Research Ethics Committee North West Haydock. We selected for the primary analysis only participants fulfilling the ACR-EULAR classification criteria (n = 665).
In a secondary analysis, we repeated the analysis with all the participants included in the dataset who all fulfilled the AECG classification criteria at inclusion or prior to inclusion in the UKPSSR (n = 668).
In ESSDAI and ClinESSDAI, we arbitrarily divided the domains into two groups. The first, defined as "major systemic" domains, were those whose weightings in the index calculation are 5 or more, and comprised the respiratory, muscular, peripheral nervous system and central nervous system and renal domains. We arbitrarily defined the second group of domains as "general' domains, comprising constitutional, lymphadenopathy, glandular, articular, cutaneous, haematological and biological domains. This division was based on a subjective view that the major systemic domains, although clinically very important, are individually relatively rare and most are difficult to measure objectively in a clinical trial context. As a consequence, the more common general domains are likely to be of greater use in evaluating the benefit of novel therapies in controlled clinical trials in pSS. The ClinESSDAI was calculated for every participant. We analysed the distribution of ESSDAI and ClinESSDAI values. The distribution of active domains and their grading were compared between ESSDAI and ClinESSDAI for several cut-off indexes values: ≥5 (moderate systemic disease activity), ≥6, ≥7, >14 (high systemic disease activity).
We analysed the level of agreement between total ESSDAI and ClinESSDAI scores. We also did a correlation analysis between individual domains of both indexes.
In an exploratory analysis, we evaluated how the participants were able to reach the MCII, when this was set at different values (3, 4 or 5) . More specifically, we assessed how many of them needed a one grade improvement in one, two or three of their active domains to reach the MCII value. We did the calculation for three cut-off values for ESSDAI and ClinESSDAI (≥5, ≥6, ≥7).
Statistical analysis
Data were analysed with Microsoft Excel for descriptive statistics and GraphPad Prism v7.01 for comparative analyses. We used the chi 2 test to compare discontinuous variables between groups. We analysed the level of agreement between total ESSDAI and ClinESSDAI scores using the method described by Bland and Altman [17] . Differences between ESSDAI and ClinESSDAI were calculated for each patient and plotted against their average. The standard deviation (SD) of such differences was calculated to estimate the limits of agreement. Spearman's test was used for correlations analyses. A p-value <0.05 was considered statistically significant. We generally made no corrections for multiple comparisons as the analyses included few comparisons, except for the correlation analyses between domains. As these analyses included many comparisons we made a Bonferroni correction and calculated a pvalue of 0.0009 for ClinESSDAI and 0.0007 ESSDAI to be statistically significant.
Results

Eligibility for clinical trials
The number of patients potentially eligible for inclusion in a clinical trial according to various disease activity index cut-off values (≥5, ≥6, ≥7, ≥14) for ESSDAI and ClinESS-DAI are reported in fig. 1 . For each selected cut-off value, there were more patients available for potential trial inclusion when ClinESSDAI was used than with use of ESSDAI. For example, with a score ≥5 (the value defining moderate disease activity), 278 patients were eligible (41.8%) with ESSDAI and 288 (43.3%) with ClinESSDAI; with a score ≥14 (the value defining high disease activity), 36 patients were eligible (5.4%) with ESSDAI and 45 (6.8%) with ClinESSDAI.
Index values and domain activity distribution
In the analysed data from UKPSSR, the ESSDAI mean value was 4.9 (SD 5.0, median 4.0, interquartile range [IQR] 1.0-7.0) and the ClinESSDAI mean value was 4.9 (SD 5.6, median 4.0, IQR 0-7.0). The detailed score distribution of ESSDAI and ClinESSDAI can be found in table 2. The distribution of patients according to defined activity levels did not differ statistically (chi 2 p = 0.57) when calculated with ESSDAI (moderate activity 36.4%, high activity 5.4%) or with ClinESSDAI (moderate activity 36.5%, high activity 6.8%). Interestingly, there were 101 more patients with an index value of 0 when ClinESSDAI was used instead of ESSDAI. These patients had only one active domain, which was the biological domain with a level of activity of 1 (n = 58) or 2 (n = 43). When the frequency of active domains in patients with an ESSDAI or ClinESSDAI score of ≥5, ≥6 or ≥7 were compared, the only statistically significant difference was the Original article Swiss Med Wkly. 2018; 148:w14588 Swiss Medical Weekly · PDF of the online version · www.smw.ch proportion of participants with an active articular domain and an ESSDAI ≥7 or ClinESSDAI ≥7 (53 and 41%, respectively; chi 2 = 5.36, p = 0.02). The distribution of domain activity levels for participants with a ClinESSDAI ≥5, currently the cut-off value most used for inclusion in clinical trials, can be found in figure 2. Figure 3 shows the differences between ESSDAI and ClinESSDAI plotted against their average. The mean difference between the two indexes was −0.07. The SD of the differences was 1.3. This value allows calculation of the lower and upper levels of agreement between both indexes, which are −2.5 and 2.4, respectively. The difference between both indexes was outside the levels of agreement for 22 (3.3%) patients, with a maximum difference value of 5. In these cases, ClinESSDAI was always higher than ESS-DAI, with values ranging from 10 to 43. We observed statistically significant correlations between domains when using ESSDAI or ClinESSDAI in the UKPSSR data, summarised for patients with activity index value ≥5 in table 3. The highest positive correlation coefficient was between the glandular and lymphadenopathy domains for ESSDAI and ClinESSDAI for different indexes cut-off values (all participants: rho = 0.196, p <0.0001 for both indexes; index ≥5: rho = 0.218, p = 0.0002, rho = 0.247, p <0.0001; index ≥6: rho = 0.263, p <0.0001, rho = 0.299, p <0.0001; index ≥7: rho = 0.313, p <0.0001, rho = 0.309, p <0.0001, for ESSDAI and ClinESSDAI, respectively, using Spearman's correlation).
Levels of agreement and correlation analysis
Ability to improve by the minimal clinically important improvement value
An MCII value of 3 has been recommended by the EU-LAR group who developed the ESSDAI and ClinESSDAI, although higher values could be chosen depending on the clinical trial and eligibility criteria [11] . The number of participants requiring a one grade improvement in one, two or three of their active domains in order to reach several MCII target values and disease activity index values are reported in table 4. To help the reader to understand the reasoning, a theoretical illustration of the ability for individual domains alone to reach certain specified MCII target values can be found in 
Discussion
We evaluated the ClinESSDAI in comparison with ESS-DAI in terms of theoretical patient recruitment and out- Table 4 : Ability to improve: number of participants from the UKPSSR requiring a one grade improvement in 1, 2, or 3 of their active domains to reach the MCII value according to several MCII target values and disease activity scores. come measurement in clinical trials using the UKPSSR dataset in participants fulfilling ACR-EULAR classification criteria, which are likely to be used as inclusion criteria for future trials. Use of ClinESSDAI potentially modestly increases the number of eligible participants for a clinical trial for any selected index cut-off value. Participants whose only active domain is the biological domain are attributed an index value of 0 in the ClinESSDAI, as this domain in not part of this activity index. Therefore, the proportion of participants with an index value of 0 is higher with ClinESSDAI than with ESSDAI. We found good agreement between ClinESSDAI and ESS-DAI, with a mean difference between them close to zero and limits of agreement smaller than the MCII of 3. However, we observed that ClinESSDAI tends to be higher than ESSDAI (maximum difference 5) in some patients with a total score of 10 or more and in all patients with a score of more than 25. Thus, caution is advised when using ClinESSDAI in patients with high disease activity; however, this affects only a small proportion of potentially eligible participants in a clinical trial. We found a consistent positive correlation between the lymphadenopathy and glandular domains, and an inverse correlation between the constitutional and respiratory/cutaneous domains, when using either ESSDAI or ClinESS-DAI at different cut-off values. This could suggest the existence of subgroups of patients with different clinical presentations, eventually related to various underlying patho- genesis pathways. As the efficacy of studied medications could differ in these patients, subgroup analysis could be useful in future clinical trials to identify which patients are more likely to respond to different treatments. In an exploratory analysis, we did not find any relationship between the correlation coefficients and the participants' characteristics (disease duration, age, anti-Ro/La positivity). Nevertheless, these preliminary results need to be confirmed in other cohorts and with longitudinal data.
Participant distributions according to the number of domains needing a onegrade improvement to reach the selected MCII, n (%)
We assessed how the ability to change is affected by the use of ClinESSDAI. We focused the analysis on patients with scores ≥5, as this cut-off value, defining moderate disease activity, is most often used in controlled studies. In our data, the use of ClinESSDAI made the MCII generally more easily reachable with a one grade improvement in one or two domains than with the use of ESSDAI. These findings can be interpreted in two ways: it could mean that ClinESSDAI will allow a more sensitive analysis and perhaps earlier detection of change in a drug trial or, conversely, it could artificially magnify the improvement of "soft" domains (e.g., articular domain with arthralgia) not necessarily representative of the full clinical picture of pSS. We attempted to evaluate whether "major systemic" and "general" domains behave differently with the use of ESS-DAI and ClinESSDAI. We believe that the activity level of major systemic domains is more difficult to assess than that of general domains. This difficulty is due to the frequent need of complementary investigations, such as imaging or nerve conduction studies, for diagnosis. These domains are often not formally assessed at each follow-up visit in routine care. In addition, investigations such as nerve conduction studies have not been validated for use as outcome tools in clinical trials. We found no significant differences in major systemic domain activity levels with the use of ESSDAI or ClinESSDAI. As major systemic domains are weighted 5 or more in the calculation of the scores, an improvement in any of these domains allows MCII values of 3, 4 or 5 to be achieved with both ESSDAI and ClinESS-DAI. In order to assess the influence of classification criteria on our results, we performed the same analyses including all UKPSSR participants, who all fulfilled the AECG classification criteria at inclusion or prior to inclusion as this is a mandatory criterion for inclusion in the registry. Among the 668 participants, we found that only 3 could be classified as pSS according to AECG criteria but not to the new ACR-EULAR criteria. These patients all showed positivity for anti-La (SSB) and not for anti-Ro (SSA), which are no longer part of ACR-EULAR classification criteria for pSS. Globally, the results are very similar and conclusions are identical with both sets of classification criteria (data not shown). However, the new ACR-EULAR criteria introduce a pSS classification different from the AECG criteria. A patient can be classified as pSS if there is a clinical suspicion of pSS and one active ESSDAI domain even without sicca symptoms. This alternative classification pathway was not assessed in the present study as it is not part of the AECG criteria, which were previously used for inclusion in the registry. Nevertheless, in our experience, the number of participants potentially affected by this alternative classification pathway is likely to be marginal and would not alter the results.
This study is limited by the fact that only baseline data were available for the analysis, with no follow-up data. In the French ASSESS cohort, the most frequent changes at follow-up were seen not only in the biological, articular, haematological and glandular domains, but also in the pulmonary domain [18] . Objective evaluation of this domain may require formal pulmonary function tests. In an Italian longitudinal study with a 12 months' follow-up, there was a tendency to improvement for the articular and cutaneous domains [19] . Whereas patients included in the UKPSSR are not necessarily representative of pSS patient populations from other countries, this cohort is representative of potentially eligible patients for clinical trials in the UK. In a context of clinical trials in pSS, ClinESSDAI would probably be used in studies investigating biomarkers or drugs targeting B-cell activity, in order to avoid the issue of collinearity of data. However, ESSDAI could also still be calculated, as biological domain items (immunoglobulins, complement, cryoglobulin) would certainly be recorded as part of the drug safety assessment.
In conclusion, our data suggest that the use of ClinESS-DAI, a modification of ESSDAI without the biological domain, is practicable, does not lead to a loss of potentially eligible patients for trials, and does not significantly alter the ability to identify changes of the indexes. However, more studies are needed, especially longitudinal data to confirm that ClinESSDAI could be used as an endpoint for clinical trials studying medications with a B-cell or other systemic effect, or in routine care for monitoring disease activity when immunological tests are not available.
